Medscape reports on a recently published article in the New England Journal of Medicine that showed that patients treated with anifrolumab had significantly more responses.

Jane E. Salmon, MD, rheumatologist at HSS, wrote in an accompanying editorial that "the current trial...showed a significant effect on the primary end point of a response at week 52 defined according to the British Isles Lupus Assessment Group (BILAG)–based Composite Lupus Assessment (BICLA).”

Dr. Salmon goes on to argue that given the need for new lupus therapies, regulators should allow more flexibility in trial design.

Read the full article at Medscape.com.